Founder/Interim Chief Executive Officer (CEO)
Qiaobing Xu's research interests lie at the intersection of material science engineering (specifically nanoscience) and biomedical applications. His work looks at developing new synthetic materials for the delivery of therapeutic biomacromolecules. In his postdoctoral research, Xu synthesized a library of lipid-like molecules, which were tested for efficacy both in vitro and in vivo in the delivery of protein and messenger RNA. Xu is currently investigating the use of drug delivery for cancer therapy and gene editing.
PhD, Harvard University, Chemistry
Postdoc associate, MIT
Professor, Tufts University